Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy

Universitätsmedizin Mannheim12 enrolled

Overview

This pilot clinical trial aims at evaluating immuno-modulating effects of palliative treatment with specifically dosed standard chemotherapeutics in patients with metastatic melanoma (AJCC stage IV) by assessing myeloid-derived suppressor cells' (MDSCs) count and activity.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Immuno-monitoring

Interventions

Immuno-monitoringOTHER

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * histologically defined metastatic melanoma patients (AJCC stage IV) * aged 18 to 80 years * at least one prior systemic anti-melanoma therapy; if BRAFV600 positive, at least one prior BRAFi therapy Exclusion Criteria: * therapy-naive patients * any contra-indications for (specific) systemic chemotherapy

Locations (1)

Universitätsmedizin Mannheim, Klinik für Dermatologie, Venerologie und Allergologie

Mannheim, Germany

Outcomes

Primary Outcomes

Immuno-monitoring

Time frame: Immediate

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.